Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
Department of Zoology, University of Malakand, Chakdara, Pakistan.
Liver Int. 2022 Mar;42(3):575-584. doi: 10.1111/liv.15133. Epub 2021 Dec 27.
We examined the associations between liver volume and other quantitative and qualitative markers of hepatic steatosis with all-cause mortality in the general population.
We included 2769 German middle-aged individuals with a median follow-up of 8.9 years (23,898 person-years). Quantitative markers used were serum liver enzymes and FIB-4 score, while qualitative markers of hepatic steatosis included magnetic resonance imaging (MRI) measurements of liver fat content and total liver volume. Cox proportional hazards models, adjusted for confounding factors, were undertaken to investigate the associations of liver volume and other markers of hepatic steatosis with all-cause mortality.
A larger MRI-assessed liver volume was associated with a nearly three-fold increased risk of all-cause mortality (Hazard Ratio = 3.16; 95% confidence interval 1.88; 5.30), independent of age, sex, body mass index, food frequency score, alcohol consumption and education level. This association was consistent in all subgroups considered (men vs. women; presence or absence of overweight/obesity, metabolic syndrome or diabetes). Higher serum liver enzyme levels and FIB-4 score were also significantly associated with higher all-cause mortality in the total population and in all subgroups. No independent associations were found between other quantitative and qualitative markers of hepatic steatosis and the risk of all-cause mortality.
We showed for the first time that larger liver volume was associated with a three-fold increase in long-term risk of all-cause mortality. This association remained significant after adjustment for age, sex, alcohol consumption, obesity and other coexisting metabolic disorders.
我们研究了在普通人群中,肝体积与其他定量和定性肝脂肪变性标志物与全因死亡率之间的关系。
我们纳入了 2769 名德国中年个体,中位随访时间为 8.9 年(23898 人年)。使用的定量标志物包括血清肝酶和 FIB-4 评分,而肝脂肪变性的定性标志物包括磁共振成像(MRI)测量的肝脂肪含量和总肝体积。采用 Cox 比例风险模型,调整混杂因素后,研究肝体积和其他肝脂肪变性标志物与全因死亡率的关系。
MRI 评估的肝体积越大,全因死亡率的风险几乎增加三倍(风险比=3.16;95%置信区间 1.88;5.30),独立于年龄、性别、体重指数、食物频率评分、饮酒和教育程度。这种关联在所有考虑的亚组中都是一致的(男性与女性;超重/肥胖、代谢综合征或糖尿病的存在或不存在)。在总人群和所有亚组中,较高的血清肝酶水平和 FIB-4 评分也与较高的全因死亡率显著相关。其他定量和定性肝脂肪变性标志物与全因死亡率的风险之间没有独立的关联。
我们首次表明,较大的肝体积与长期全因死亡率风险增加三倍相关。在调整年龄、性别、饮酒、肥胖和其他并存的代谢紊乱后,这种关联仍然显著。